Search

With substantial temperature differentials between summer and winter in polar regions, there exists a pressing necessity for flexible sensors capable of functioning across a broad temperature spectrum to facilitate the construction of a more intelligent human-machine interface. Nevertheless, developing flexible sensors resilient to extremely low temperatures remains a significant challenge. In this study, we present an organohydrogel capable of functioning ranging from ambient to -78 °C, enabling real-time monitoring of multi-source signals, including motion, physiology, speech, and pressure. We synthesize organohydrogel employing a singular methodology: interpenetrating network structures as matrix frameworks, dynamic hydrophobic linkages as the physical cross-linking points, and incorporating a bionic binder. H-Bonding and chain entanglement synergistic supramolecular interactions build the organohydrogel matrix with microphase-separated domains, which, together with the combination of binary solvents and inorganic salts, allows it to exhibit excellent properties, including large stretchability (≈1700%), high ionic conductivity (1.57 S m -1 ), admirable sensing sensitivity performance (gauge factor: GF = 6.47, S = 0.32 kPa -1 ), an exceptionally low-pressure detection threshold (≈1 Pa), enables wireless transmission of distress signals through human-machine interaction even at -78 °C, which makes it possible to use it in polar exploration and to give robots a "sense of touch" for a variety of deep-diving tasks.

Context: High-dose methylprednisolone pulse therapy and oral high-dose prednisone are two common treatments for pediatric nephrotic syndrome (NS). While both treatments have shown effectiveness for patients with pediatric NS to some extent, a clear comparison of their efficacy and safety remains elusive, posing a challenge for clinicians when devising treatment plans., Objective: The study intended to compare the efficacy and safety of high-dose methylprednisolone pulse therapy and conventional oral high-dose prednisone for pediatric patients with NS, to provide more accurate treatment recommendations for clinicians to optimize their treatment plans, improve their QoL, and prevent complications., Design: The research team conducted a randomized controlled trial., Setting: The study took place at the Second Affiliated Hospital of Fujian Medical University in Quanzhou, China., Participants: Participants were 60 patients with pediatric NS who received treatment at the hospital between November 2020 and March 2022., Interventions: The research team randomly divided participants into two groups, each comprising 30 patients: (1) the intervention group, which received high-dose methylprednisolone pulse therapy, and (2) the conventional group, which received oral high-dose prednisone., Outcome Measures: The research team measured: (1) clinical efficacy rates, the primary outcome measure; (2) time to symptom relief; (3) laboratory indicators, including blood urea nitrogen (BUN), serum creatinine (SCr), serum globulin (GLB), and 24-hour urine protein quantification; and (4) incidence of adverse events., Results: Compared to the conventional group, the intervention group's: (1) clinical efficacy rate was significantly higher (P < .05); (2) resolution times for edema (P < .001) and urine protein turning negative (P < .001) were significantly shorter; (3) levels of BUN (P < .001), SCr (P < .001), GLB (P < .001), and 24-hour urine protein quantification (P < .001) were significantly lower; and (4) incidence of adverse reactions was significantly higher (P < .001)., Conclusions: High-dose methylprednisolone pulse therapy demonstrated better efficacy in treating pediatric NS patients, showing a shorter time to symptom relief, but it may also entail a higher risk of adverse reactions compared to conventional oral high-dose prednisone. Clinicians should consider the specific circumstances and needs of pediatric patients when selecting a treatment.